

Appl. No. 10/612,832  
Amld. dated November 14, 2005

PATENT

**Amendments to the Specification:**

*Instructions for amending the specification are based upon the paragraph numbering in the substitute specification mailed September 6, 2005.*

*Please replace paragraph [0026] with following amended paragraph:*

[0026] In a further preferred embodiment, the reagent reacts with a protein containing the amino acid sequence CEPDY (SEQ ID NO:13) as the core sequence of the epitope. The epitope in question occurs, amongst other things, twice in the CD30 antigen. The identification of an epitope that is recognised by the reagent according to the invention is easily possible using methods commonly used by experts, as is explained in more detail in the examples for the CEPDY (SEQ ID NO:13) epitope.

*Please replace the paragraph [0047] with following amended paragraph:*

[0047] The mapping of the epitope to which the antibody according to the invention binds showed that this binds to a peptide sequence which occurs twice in the extracellular domain of CD30. The antibody secreted by the cell line DSZ1 according to the invention showed two strong signals with peptides derived from CD30 (cf. Figure 3): Spot 16 (with the sequence  $^{64}\text{DCRKQCEPDYYLD}^{76}$  (SEQ ID NO:11)) and Spot 74 ( $^{239}\text{GDCRKQCEPDYYL}^{250}$  (SEQ ID NO:12)). An extensive mapping of the epitope using substitution analysis gave the amino acid residue CEPDY (SEQ ID NO:13) as the core sequence for the interaction. Both epitopes bind the antibody secreted by the cell line according to the invention and the binding was not lost if only one of the epitopes was mutated, whilst mutation in both epitopes led to the loss of the antibody recognition.

*Please replace the paper copy of the substitute sequence listing filed September 15, 2004 with the paper copy of the second substitute sequence listing attached in the Appendix.*